Display options
Cite
Regan D, Dow S. Manipulation of Innate Immunity for Cancer Therapy in Dogs. Vet Sci. 2015;2(4):423-439doi: 10.3390/vetsci2040423.
Regan, D., & Dow, S. (2015). Manipulation of Innate Immunity for Cancer Therapy in Dogs. Veterinary sciences, 2(4), 423-439. https://doi.org/10.3390/vetsci2040423
Regan, Daniel, and Dow, Steven. "Manipulation of Innate Immunity for Cancer Therapy in Dogs." Veterinary sciences vol. 2,4 (2015): 423-439. doi: https://doi.org/10.3390/vetsci2040423
Regan D, Dow S. Manipulation of Innate Immunity for Cancer Therapy in Dogs. Vet Sci. 2015 Dec 01;2(4):423-439. doi: 10.3390/vetsci2040423. PMID: 29061951; PMCID: PMC5644648.
Copy Download .nbib Format: NLM
Share it on

Vet Sci. 2015 Dec 01;2(4):423-439. doi: 10.3390/vetsci2040423.

Manipulation of Innate Immunity for Cancer Therapy in Dogs.

Veterinary sciences

Daniel Regan, Steven Dow

Affiliations

  1. Flint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80525, USA. [email protected].
  2. The Center for Immune and Regenerative Medicine, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80525, USA. [email protected].
  3. Flint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80525, USA. [email protected].
  4. The Center for Immune and Regenerative Medicine, Department of Clinical Sciences, Colorado State University, Ft. Collins, CO 80525, USA. [email protected].

PMID: 29061951 PMCID: PMC5644648 DOI: 10.3390/vetsci2040423

Abstract

Over the last one to two decades, the field of cancer immunotherapy has rapidly progressed from early preclinical studies to a successful clinical reality and fourth major pillar of human cancer therapy. While current excitement in the field of immunotherapy is being driven by several major breakthroughs including immune checkpoint inhibitors and adoptive cell therapies, these advances stem from a foundation of pivotal studies demonstrating the immune systems role in tumor control and eradication. The following will be a succinct review on veterinary cancer immunotherapy as it pertains to manipulation of the innate immune system to control tumor growth and metastasis. In addition, we will provide an update on recent progress in our understanding of the innate immune system in veterinary tumor immunology, and how these gains may lead to novel therapies for the treatment of cancer in companion animals.

Keywords: cancer; dog; innate immunity; macrophage; monocyte; treatment

References

  1. Cancer Immunol Immunother. 2002 Aug;51(6):293-8 - PubMed
  2. Immunobiology. 2017 Jan;222(1):11-20 - PubMed
  3. Eur J Immunol. 2010 Nov;40(11):2969-75 - PubMed
  4. Cancer Res. 2015 Oct 15;75(20):4260-4 - PubMed
  5. BMC Vet Res. 2012 Oct 31;8:209 - PubMed
  6. Clin Cancer Res. 2011 Oct 1;17(19):6118-24 - PubMed
  7. Cancer Immunol Immunother. 2008 Jun;57(6):907-12 - PubMed
  8. Cell Death Differ. 2010 Apr;17(4):616-23 - PubMed
  9. Nat Rev Immunol. 2015 Jul;15(7):405-14 - PubMed
  10. J Am Vet Med Assoc. 1993 Jan 15;202(2):304-6 - PubMed
  11. J Immunol. 2011 Oct 1;187(7):3538-45 - PubMed
  12. J Feline Med Surg. 2006 Dec;8(6):400-11 - PubMed
  13. J Immunol Methods. 1994 Sep 14;174(1-2):83-93 - PubMed
  14. J Am Vet Med Assoc. 2008 May 15;232(10):1504-10 - PubMed
  15. J Am Vet Med Assoc. 1995 May 15;206(10):1555-60 - PubMed
  16. Curr Top Microbiol Immunol. 2000;247:157-70 - PubMed
  17. Cancer Immunol Immunother. 2008 Nov;57(11):1679-83 - PubMed
  18. Nat Rev Cancer. 2013 Oct;13(10 ):739-52 - PubMed
  19. Nature. 2011 Jun 08;475(7355):222-5 - PubMed
  20. J Am Anim Hosp Assoc. 1995 Sep-Oct;31(5):439-47 - PubMed
  21. Cancer Res. 2006 Jan 15;66(2):605-12 - PubMed
  22. Immunol Rev. 2008 Apr;222:155-61 - PubMed
  23. Vet Immunol Immunopathol. 1993 Sep;38(1-2):45-56 - PubMed
  24. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6970-5 - PubMed
  25. Immunity. 2014 Jul 17;41(1):49-61 - PubMed
  26. Eur J Cancer. 1974 Dec;10(12):775-80 - PubMed
  27. Vet Comp Oncol. 2011 Mar;9(1):55-64 - PubMed
  28. Immunity. 2004 Aug;21(2):137-48 - PubMed
  29. Cancer Res. 2014 May 15;74(10):2663-8 - PubMed
  30. Cancer Immunol Immunother. 2006 Mar;55(3):237-45 - PubMed
  31. Vet Immunol Immunopathol. 1992 Jun;33(1-2):1-16 - PubMed
  32. Cancer Immunol Immunother. 2013 Dec;62(12):1757-68 - PubMed
  33. J Am Vet Med Assoc. 2011 Jan 15;238(2):195-206 - PubMed
  34. J Leukoc Biol. 2004 Feb;75(2):163-89 - PubMed
  35. Cancer Biother. 1994 Fall;9(3):237-44 - PubMed
  36. Nat Rev Immunol. 2012 Mar 22;12(4):253-68 - PubMed
  37. Nat Rev Cancer. 2009 May;9(5):361-71 - PubMed
  38. Oncoimmunology. 2014 Dec 15;3(10):e956579 - PubMed
  39. Postgrad Med J. 2003 Dec;79(938):672-80 - PubMed
  40. Nat Rev Immunol. 2009 Mar;9(3):162-74 - PubMed
  41. Adv Exp Med Biol. 2014;804:341-53 - PubMed
  42. J Immunother Cancer. 2013 Sep 23;1:16 - PubMed
  43. Clin Cancer Res. 1995 Dec;1(12):1595-601 - PubMed
  44. Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90 - PubMed
  45. J Clin Invest. 2014 Dec;124(12):5466-80 - PubMed
  46. J Exp Med. 2015 Jun 29;212(7):1043-59 - PubMed
  47. Cancer Cell. 2009 Sep 8;16(3):183-94 - PubMed
  48. PLoS One. 2012;7(3):e33274 - PubMed
  49. Semin Oncol. 2015 Aug;42(4):523-38 - PubMed
  50. Cancer Immunol Res. 2013 Aug;1(2):77-84 - PubMed
  51. J Immunol. 2008 Oct 15;181(8):5791-802 - PubMed
  52. Mol Biother. 1991 Dec;3(4):207-13 - PubMed
  53. Nat Rev Cancer. 2012 Mar 22;12(4):265-77 - PubMed
  54. Cancer Gene Ther. 2006 Mar;13(3):306-17 - PubMed
  55. Oncologist. 2006 Apr;11(4):397-408 - PubMed
  56. Curr Opin Pharmacol. 2014 Aug;17:17-21 - PubMed
  57. J Clin Oncol. 1992 Aug;10 (8):1310-6 - PubMed
  58. Clin Cancer Res. 1996 Apr;2(4):721-34 - PubMed
  59. J Immunol. 2009 Apr 15;182(8):4499-506 - PubMed
  60. J Clin Immunol. 2005 Nov;25(6):511-21 - PubMed
  61. Cancer Immunol Immunother. 2010 Mar;59(3):441-52 - PubMed
  62. Expert Opin Ther Targets. 2012 Jan;16(1):85-101 - PubMed
  63. Nat Rev Cancer. 2004 Jan;4(1):71-8 - PubMed
  64. Annu Rev Med. 2015;66:97-110 - PubMed
  65. Vet Comp Oncol. 2013 Dec;11(4):296-305 - PubMed
  66. Expert Opin Drug Deliv. 2008 Jan;5(1):11-24 - PubMed
  67. J Vet Intern Med. 2010 Nov-Dec;24(6):1439-44 - PubMed
  68. Trends Immunol. 2011 Jan;32(1):19-25 - PubMed
  69. J Natl Cancer Inst. 1989 Jun 21;81(12 ):935-8 - PubMed
  70. Curr Opin Drug Discov Devel. 2000 Mar;3(2):214-21 - PubMed
  71. J Innate Immun. 2012;4(1):16-30 - PubMed
  72. Nat Rev Cancer. 2008 Oct;8(10):782-98 - PubMed
  73. Clin Cancer Res. 2014 Apr 1;20(7):1747-56 - PubMed
  74. Front Immunol. 2013 Dec 23;4:481 - PubMed
  75. Cancer Immunol Immunother. 2014 May;63(5):419-35 - PubMed
  76. Front Immunol. 2012 Nov 08;3:328 - PubMed
  77. Cancer Treat Res. 1993;62:101-7 - PubMed
  78. Cancer. 1997 Apr 1;79(7):1409-21 - PubMed
  79. Cell. 2006 Jan 27;124(2):263-6 - PubMed
  80. PLoS One. 2014 Jan 13;9(1):e85222 - PubMed
  81. J Immunol. 1999 Aug 1;163(3):1552-61 - PubMed
  82. Curr Opin Investig Drugs. 2003 Jun;4(6):686-90 - PubMed
  83. Clin Cancer Res. 1999 Dec;5(12):4249-58 - PubMed
  84. Hum Gene Ther. 2005 Aug;16(8):937-46 - PubMed
  85. Immunobiology. 2013 Nov;218(11):1402-10 - PubMed
  86. Blood. 2012 Jan 19;119(3):651-65 - PubMed
  87. Bibl Haematol. 1975 Oct;(43):522-3 - PubMed
  88. Cancer Immunol Immunother. 1994 Aug;39(2):84-92 - PubMed
  89. Nat Immunol. 2000 Dec;1(6):515-20 - PubMed
  90. Oncoimmunology. 2012 Nov 1;1(8):1248-1257 - PubMed
  91. Cancer Immunol Immunother. 2013 May;62(5):909-18 - PubMed

Publication Types